Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous extended letrozole in endocrine-responsive breast cancer
ACTRN12608000243314Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of letrozole in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Disease-free survival. Started Sep 2009; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12608000243314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000243314.